International Joint Center for Biomedical Innovation (JCBI)     International Joint Center for Biomedical Innovation (JCBI)
English
中文版
 
Position: JCBI HOME/News/Content
 
Happy news: the research paper of our center has been successfully accepted for publication on Nano Letters

Recently, the research paper with the title of “Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy” was accepted for publication on Nano Letters.

Nanotechnology-based RNA interference (RNAi) has shown great promise in overcoming the limitations of traditional clinical treatments for glioblastoma (GBM). However, because of the complexity of brain physiology, simple blood−brain barrier (BBB) penetration or tumor-targeting strategies cannot entirely meet the demanding requirements of different therapeutic delivery stages. Herein, we developed a charge conversional biomimetic nanoplatform with a three-layer core−shell structure to programmatically overcome persistent obstacles in siRNA delivery to GBM. The resulting nanocomplex presents good biocompatibility, prolonged blood circulation, high BBB transcytosis, effective tumor accumulation, and specific uptake by tumor cells in the brain. Moreover, red blood cell membrane (RBCm) disruption and effective siRNA release can be further triggered elegantly by charge conversion from negative to positive in the endo/lysosome (pH 5.0−6.5) of tumor cells, leading to highly potent target-gene silencing with a strong anti-GBM effect. Our study provides an intelligent biomimetic nanoplatform tailored for systemically siRNA delivery to GBM, leveraging Angiopep-2 peptide-modified, immune-free RBCm and charge conversional components. Improved therapeutic efficacy, higher survival rates, and minimized systemic side effects were achieved in orthotopic U87MG-luc human glioblastoma tumor-bearing nude mice.

Nano Letters is a top journal around the word and the current IF is 12.279.

Dr. Yan Zou and P.h.D candidate Yanjie Liu are shared first authors, Prof. Meng Zheng, Prof. Omid C. Farokhzad and Prof. Bingyang Shi are shared corresponding authors. This work was supported by the National Natural Science Foundation of China (NSFC 31600809, 31640027, 51803049, and U1604177), National Postdoctoral Program for Innovative Talents (BX201700070), the National Health and Medical Research Council (NHMRC) Dementia Fellowship (APP1111611), NHMRC Project grant (GNT1166024), China Postdoctoral Science Foundation (2017M620299), the National Key Technologies R&D Program of China  (2018YFA0209800), Macquarie University Research Fellow-ship, and the Program of China’s 1000-talents Plan.


 
 International Joint Center
for Biomedical Innovation (JCBI)
Visits: 
  Address
School of Life Sciences, Henan University, Jin Ming Avenue, Kaifeng, Henan, 475004, China
  Contact
Email: jcbi@vip.henu.edu.cn
facebooktwitteryoutubeg+